Table 3.
Patient categorization from brain homogenate samples.
| Case Information | Brain Tissue | AM CSF |
PM CSF | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Sex | Age at onset | Age at death | Primary Pathology | Thal Phase | CERAD Stage | Braak Stage | ADNC | LRP Classification | Frontal Cortex | Amygdala | LP to death (y) | Result | Result |
| 1 | Male | NA | 84 | Normal | A0 | C0 | I | Not | None | − | − | 1.8 | − | |
| 2 | Male | 65 | 71 | CBD | A3 | C1 | I | Low | None | 2/3 | − | 2.9 | − | |
| 3 | Female | 65 | 76 | AD | A3 | C3 | VI | High | None | − | − | 4.7 | − | − |
| 4 | Female | 58 | 66 | AD | A3 | C3 | VI | High | None | − | − | 3.0 | − | − |
|
| ||||||||||||||
| 5 | Female | 72 | 84 | AD | A3 | C2 | VI | High | Amygdala | − | 2.7 | − | ||
| 6 | Female | 83 | 90 | AD + PSP | A3 | C2 | VI | High | Amygdala | − | 2/3 | 0.9 | + | |
| 7 | Female | 84 | 91 | AD | A3 | C3 | VI | High | Amygdala | 2/3 | + | 4.6 | − | |
| 8 | Male | 75 | 84 | AD | A3 | C2 | VI | High | Amygdala | 2/3 | + | 4.9 | − | + |
| 9 | Female | 56 | 66 | FTLD TDP-43 | A0 | C0 | I | Not | Amygdala | − | − | 3.8 | − | − |
| 10 | Male | 69 | 76 | AD | A3 | C3 | VI | High | Amygdala | − | − | 5.5 | − | − |
| 11 | Male | 55 | 73 | AD | A3 | C3 | V | High | Amygdala | − | − | 1.9 | − | − |
| 12 | Male | 77 | 86 | AD | A3 | C3 | V | High | Amygdala | − | + | 5.3 | − | + |
| 13 | Female | 79 | 87 | AD | A3 | C3 | IV | Intermediate | Amygdala | − | + | 5.3 | − | + |
| 14 | Female | 90 | 100 | AD | A3 | C3 | V | High | Amygdala | − | − | 8.0 | − | − |
|
| ||||||||||||||
| 15 | Male | 54 | 67 | LBD | A1 | C2 | I | Low | Limbic/Neocortical | + | + | 8.1 | + | |
| 16 | Male | 72 | 81 | LBD | A3 | C2 | V | High | Limbic/Neocortical | + | + | 3.7 | + | |
| 17 | Male | 59 | 71 | LBD | A3 | C2 | IV | Intermediate | Limbic/Neocortical | + | + | 3.5 | + | |
| 18 | Male | 63 | 71 | LBD | A3 | C2 | III | Intermediate | Limbic/Neocortical | + | + | 1.2 | + | |
| 19 | Male | 66 | 71 | LBD | A3 | C3 | VI | High | Limbic/Neocortical | + | + | 1.7 | + | + |
| 20 | Male | 62 | 73 | LBD | A3 | C1 | II | Low | Limbic/Neocortical | + | + | 6.8 | + | + |
| 21 | Male | 52 | 72 | LBD | A2 | C2 | V | Intermediate | Limbic/Neocortical | + | + | 9.3 | + | + |
| 22 | Female | 51 | 59 | LBD | A3 | C3 | VI | High | Limbic/Neocortical | + | + | 2.7 | + | + |
Abbreviations: AM: Antemortem, PM: Postmortem, ADNC: Alzheimer’s disease neuropathological change NA: not applicable. LRP: Lewy Related Pathology, CSF: cerebrospinal fluid. CBD: corticobasal degeneration, AD: Alzheimer’s disease, PSP: progressive supranuclear Palsy, FTLD TDP-43: frontotemporal lobar degeneration TAR DNA-binding protein 43, LBD: Lewy-body disease. Inconclusive cases have 2/3 replicate wells that were positive. Brain tissue samples were analyzed at 10-8 dilution. Positive results indicate 3/3 replicates were positive and negative results indicate 0/3 replicates were positive. Amygdala tissue could not be obtained for case 5.